Back to Research Home
WSTWest Pharmaceutical Services Inc
Health Care · Health Care Supplies · Large
$392.15−0.48%
As of 23 Oct 2026Mkt cap $24.1B
Stage 13
WAIT
Fundamentals
40.2/75
Technical
5.6/15
Independent
45.8/90
GCAE viewelevated earnings event risk blocks an independent BUY decision
Price
- 1M
- +5.0%
- 3M
- +18.4%
- 6M
- +28.1%
- 1Y
- +41.6%
Financials & valuation
Cached filing evidence · as of 2026-10-02
Valuation
- P/E
- 50.2xHist median 40.4x
- Forward P/E
- —No validated forward-estimate source
- Price / FCF
- 65.3x
- FCF yield
- 1.5%
Quality
- ROIC
- 18.7%
- Operating margin
- 19.7%
- FCF margin
- 15.3%
- Current ratio
- 3.0x
Growth
- Revenue growth
- +6.3%Latest FY YoY
- Revenue CAGR
- +2.1%
- EPS CAGR
- −5.9%
- FCF CAGR
- +9.1%
Capital
- Share-count trend
- −1.7%3Y annualised
- Net cash
- $588M-0.8x OCF
Annual trend
- CAGR 2021–2025
- +2.1%
- Latest · 2025
- $3B
- YoY
- +6.3%
GCAE Research
- Quality Research
- NOT FLAGGED
- Acceleration Radar
- NOT FLAGGED
- THE ONE
- NOT FLAGGED
- Final / Opportunity
- NOT FLAGGED
Key takeaway
elevated earnings event risk blocks an independent BUY decision
Unresolved question
No reliable unresolved question is available from the current committed evidence.
Watch next
- Next earnings · 2026-10-29
More details & evidence
Production decision
- Stage 13
- WAIT
- Technical state
- extended
- Rotation
- tailwind
- Evidence
- fresh
Presentation freshness
- Stage 11 market
- 2026-10-23 · Massive
- Financial cache
- 2026-10-02
- Quality Research
- NOT FLAGGED
- THE ONE
- NOT FLAGGED
Authority
- Company page
- Presentation only
- Scores
- Frozen GCAE production outputs
- Research
- Research-only lanes; no score override
- Private portfolio
- Not loaded